Adenoviral gene transfer of active human transforming growth factor-β2 elevates intraocular pressure and reduces outflow facility in rodent eyes

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 4, 2010, Pages 2067-2076

  Shepard, Allan R ^a   Cameron Millar, J ^a   Pang, Iok Hou ^a   Jacobson, Nasreen ^a   Wang, Wan Heng ^a   Clark, Abbot F ^b  

^a ALCON RESEARCH LTD   (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR OUTFLOW; ARTICLE; CHO CELL; CONTROLLED STUDY; CORRELATIONAL STUDY; EXPRESSION VECTOR; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INTRAOCULAR HYPERTENSION; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN ANGLE GLAUCOMA; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RISK FACTOR; SHUTTLE VECTOR; STAINING; TONOMETER; TRABECULAR MESHWORK; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; WILD TYPE; ADENOVIRUS; AMINO ACID SEQUENCE; ANIMAL; AQUEOUS HUMOR; BAGG ALBINO MOUSE; COMPARATIVE STUDY; CRICETULUS; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HAMSTER; INTRAOCULAR PRESSURE; METABOLISM; MOLECULAR GENETICS; OCULOPLETHYSMOGRAPHY; PATHOLOGY; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WISTAR RAT;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; AQUEOUS HUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PLASMIDS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TONOMETRY, OCULAR; TRABECULAR MESHWORK; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA2;

EID: 77951230645     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4567     Document Type: Article

References (73)

1. Quigley H.A, Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
2. Lichter P.R, Musch D.C, Gillespie B.W, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study com-paring initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953.
3. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000; 130:429-440.
4. Leske M.C, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56.
5. Kass M.A, Heuer D.K, Higginbotham E.J, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713; discussion 829-730.
6. Acott T.S, Kingsley P.D, Samples J.R, Van Buskirk E.M. Human trabecular meshwork organ culture: morphology and glycosaminoglycan synthesis. Invest Ophthalmol Vis Sci. 1988;29:90-100.
7. Lütjen-Drecoll E, Shimizu T, Rohrbach M, Rohen J.W. Quantitative analysis of 'plaque material' in the inner- and outer wall of Schlemm's canal in normal- and glaucomatous eyes. Exp Eye Res. 1986;42:443-455.
8. Rohen J.W. Why is intraocular pressure elevated in chronic simple glaucoma? Anatomical considerations. Ophthalmology. 1983;90: 758-765.
9. Segawa K. Electron microscopic changes of the trabecular tissue in primary open-angle glaucoma. Ann Ophthalmol. 1979;11:49-54.
10. Clark A.F, Wilson K, McCartney M.D, Miggans S.T, Kunkle M, Howe W. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1994;35:281-294.
11. Read A.T, Chan D.W, Ethier C.R. Actin structure in the outflow tract of normal and glaucomatous eyes. Exp Eye Res. 2007;84:214-226.
12. Liu Y, Vollrath D. Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma. Hum Mol Genet. 2004;13: 1193-1204.
13. Yam G.H, Gaplovska-Kysela K, Zuber C, Roth J. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest Ophthalmol Vis Sci. 2007;48:1683-1690.
14. Jacobson N, Andrews M, Shepard A.R, et al. Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor. Hum Mol Genet. 2001;10:117-125.
15. Joe M.K, Sohn S, Hur W, Moon Y, Choi Y.R, Kee C. Accumulation of mutant myocilins in ER leads to ER stress and potential cytotoxicity in human trabecular meshwork cells. Biochem Biophys Res Commun. 2003;312:592-600.
16. Shepard A.R, Jacobson N, Millar J.C, et al. Glaucoma-causing myocilin mutants require the peroxisomal targeting signal-1 receptor (PTS1R) to elevate intraocular pressure. Hum Mol Genet. 2007; 16:609-617.
17. Rozsa F.W, Shimizu S, Lichter P.R, et al. GLC1A mutations point to regions of potential functional importance on the TIGR/MYOC protein. Mol Vis. 1998;4:20.
18. Inatani M, Tanihara H, Katsuta H, Honjo M, Kido N, Honda Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 2001;239: 109-113.
19. Min S.H, Lee T.I, Chung Y.S, Kim H.K. Transforming growth factorbeta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol. 2006;20:162-165.
20. Ochiai Y, Ochiai H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn J Ophthalmol. 2002;46:249-253.
21. Picht G, Welge-Luessen U, Grehn F, Lütjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 2001;239:199-207.
22. Schlotzer-Schrehardt U, Zenkel M, Kuchle M, Sakai LY, Naumann GO. Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res. 2001;73:765-780.
23. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
24. Yamamoto N, Itonaga K, Marunouchi T, Majima K. Concentration of transforming growth factor beta2 in aqueous humor. Ophthalmic Res. 2005;37:29-33.
25. Koliakos GG, Schlotzer-Schrehardt U, Konstas AG, Bufidis T, Georgiadis N, Dimitriadou A. Transforming and insulin-like growth factors in the aqueous humour of patients with exfoliation syndrome. Graefes Arch Clin Exp Ophthalmol. 2001;239:482-487.
26. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res. 1990;9:963-969.
27. Fuchshofer R, Birke M, Welge-Lussen U, Kook, Lütjen-Drecoll E. Transforming growth factor-beta 2 modulated extracellular matrix component expression in cultured human optic nerve head astrocytes. Invest Ophthalmol Vis Sci. 2005;46:568-578.
28. Fleenor D.L, Shepard A.R, Hellberg P.E, Jacobson N, Pang I.H, Clark A.F. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci. 2006;47:226-234.
29. Wordinger R.J, Clark A.F, Agarwal R, et al. Cultured human trabecular meshwork cells express functional growth factor receptors. Invest Ophthalmol Vis Sci. 1998;39:1575-1589.
30. Cao Y, Wei H, Pfaffl M.W, Da B. [Effect of transforming growth factor beta 2 on phagocytosis in cultured bovine trabecular meshwork cells]. Ophthalmologe. 2003;100:535-538.
31. Gottanka J, Chan, Eichhorn M, Lütjen-Drecoll E, Ethier C.R. Effects of TGF-beta2 in perfused human eyes. Invest Ophthalmol Vis Sci. 2004;45:153-158.
32. Bachmann B, Birke M, Kook, Eichhorn M, Lütjen-Drecoll E. Ultrastructural and biochemical evaluation of the porcine anterior chamber perfusion model. Invest Ophthalmol Vis Sci. 2006;47: 2011-2020.
33. Von Seggern D.J, Aguilar E, Kinder K, et al. In vivo transduction of photoreceptors or ciliary body by intravitreal injection of pseudotyped adenoviral vectors. Mol Ther. 2003;7:27-34.
34. Borrás T, Tamm E.R, Zigler J.S Jr. Ocular adenovirus gene transfer varies in efficiency and inflammatory response. Invest Ophthalmol Vis Sci. 1996;37:1282-1293.
35. Gleizes P.E, Munger J.S, Nunes I, et al. TGF-beta latency: biological significance and mechanisms of activation. Stem Cells. 1997;15: 190-197.
36. Zacchigna L, Vecchione C, Notte A, et al. Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell. 2006;124:929-942.
37. Brunner A.M, Marquardt H, Malacko A.R, Lioubin M.N, Purchio A.F. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor: expression and characterization of mutant proteins. J Biol Chem. 1989;264:
38. Samuel S.K, Hurta R.A, Kondaiah P, et al. Autocrine induction of tumor protease production and invasion by a metallothioneinregulated TGF-beta 1 (Ser223, 225). EMBO J. 1992;11:1599-1605.
39. Srinivasan Y, Lovicu F.J, Overbeek P.A. Lens-specific expression of transforming growth factor beta1 in transgenic mice causes anterior subcapsular cataracts. J Clin Invest. 1998;101:625-634.
40. Migaly J, Lieberman J, Long W, Fisher C, Rolandelli R.H. Effect of adenoviral-mediated transfer of transforming growth factor-beta1 on colonic anastomotic healing. Dis Colon Rectum. 2004;47: 1699-1705.
41. Li D, Liu Y, Chen J, et al. Suppression of atherogenesis by delivery of TGFbeta1ACT using adeno-associated virus type 2 in LDLR knockout mice. Biochem Biophys Res Commun. 2006;344:701-707.
42. Yu Q, Stamenkovic I. Transforming growth factor-beta facilitates breast carcinoma metastasis by promoting tumor cell survival. Clin Exp Metastasis. 2004;21:235-242.
43. Wang W.H, Millar J.C, Pang I.H, Wax M.B, Clark A.F. Noninvasive measurement of rodent intraocular pressure with a rebound tonometer. Invest Ophthalmol Vis Sci. 2005;46:4617-4621
44. Anderson R.D, Haskell R.E, Xia H, Roessler B.J, Davidson B.L. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther. 2000;7:1034-1038.
45. Pang I.H, Shade D.L, Clark A.F, Steely H.T, DeSantis L. Preliminary characterization of a transformed cell strain derived from human trabecular meshwork. Curr Eye Res. 1994;13:51-63.
46. Shepard A.R, Jacobson N, Fingert J.H, Stone E.M, Sheffield V.C, Clark F. Delayed secondary glucocorticoid responsiveness of MYOC in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2001;42:3173-3181.
47. Shepard A.R, Jacobson N, Clark A.F. Importance of quantitative PCR primer location for short interfering RNA efficacy determination. Anal Biochem. 2005;344:287-288.
48. Haberberger T.C, Kupfer K, Murphy J.E. Profiling of genes which are differentially expressed in mouse liver in response to adenoviral vectors and delivered genes. Gene Ther. 2000;7:903-909.
49. Li J, Tripathi B.J, Tripathi R.C. Modulation of pre-mRNA splicing and protein production of fibronectin by TGF-beta2 in porcine trabecular cells. Invest Ophthalmol Vis Sci. 2000;41:3437-3443.
50. Robertson J.V, Nathu Z, Najjar A, Dwivedi, Gauldie J, West-Mays JA. Adenoviral gene transfer of bioactive TGFbeta1 to the rodent eye as a novel model for anterior subcapsular cataract. Mol Vis. 2007; 13:457-469.
51. Wang W.H, McNatt L.G, Pang I.H, et al. Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure. J Clin Invest. 2008;118:1056-1064.
52. Kim S.J, Jeang K.T, Glick A.B, Sporn M.B, Roberts A.B. Promoter sequences of the human transforming growth factor-beta 1 gene responsive to transforming growth factor-beta 1 autoinduction. J Biol Chem. 1989;264:7041-7045.
53. Blanchette F, Day R, Dong W, Laprise M.H, Dubois C.M. TGFbeta1 regulates gene expression of its own converting enzyme furin. J Clin Invest. 1997;99:1974-1983.
54. Chagraoui H, Giraudier S, Vainchenker W, Wendling F. Adenoviral supply of active transforming growth factor-beta1 (TGF-beta1) did not prevent lethality in transforming growth factor-beta1-knockout embryos. Eur Cytokine Netw. 2001;12:561-567.
55. Kolb M, Bonniaud P, Galt T, et al. Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. Am J Respir Cell Mol Biol. 2002;27:141-150.
56. Sime P.J, Xing Z, Graham F.L, Csaky K.G, Gauldie J. Adenovectormediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997; 100:768-776.
57. Aihara M, Lindsey J.D, Weinreb R.N. Aqueous humor dynamics in mice. Invest Ophthalmol Vis Sci. 2003;44:5168-5173.
58. Clark A.F, Pang I.H. Advances in glaucoma therapeutics. Expert Opin Emerg Drugs. 2002;7:141-163.
59. Robertson J, Golesic E, Gauldie J, West-Mays J.A. Ocular gene transfer of active TGF_ induces changes in anterior segment morphology and elevated IOP in rats. Invest Ophthalmol Vis Sci. 2010;51:308-318.
60. Flugel-Koch C, Ohlmann A, Piatigorsky J, Tamm E.R. Disruption of anterior segment development by TGF-beta1 overexpression in the eyes of transgenic mice. Dev Dyn. 2002;225:111-125.
61. Zhao S, Overbeek P.A. Elevated TGFbeta signaling inhibits ocular vascular development. Dev Biol. 2001;237:45-53.
62. Budenz D.L, Bennett J, Alonso L, Maguire A. In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1995;36:2211-2215.
63. Hoffman L.M, Maguire A.M, Bennett J. Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery. Invest Ophthalmol Vis Sci. 1997;38: 2224-2233.
64. Yang Y, Nunes F.A, Berencsi K, Furth E.E, Gonczol E, Wilson J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994;91:4407-4411.
65. Tripathy S.K, Black H.B, Goldwasser E, Leiden J.M. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 1996;2:545-550.
66. Kee C, Sohn S, Hwang J.M. Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo. Invest Ophthalmol Vis Sci. 2001;42:2856-2860.
67. Andrawiss M, Maron A, Beltran W, et al. Adenovirus-mediated gene transfer in canine eyes: a preclinical study for gene therapy of human uveal melanoma. J Gene Med. 2001;3:228-239.
68. Borrás T, Gabelt B.T, Klintworth G.K, Peterson J.C, Kaufman P.L. Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. J Gene Med. 2001;3:437-449.
69. Hangai M, Tanihara H, Honda Y, Kaneda Y. Introduction of DNA into the rat and primate trabecular meshwork by fusogenic liposomes. Invest Ophthalmol Vis Sci. 1998;39:509-516.
70. Borrás T, Brandt C.R, Nickells R, Ritch R. Gene therapy for glaucoma: treating a multifaceted, chronic disease. Invest Ophthalmol Vis Sci. 2002;43:2513-2518.
71. Liu X, Brandt C.R, Gabelt B.T, Bryar P.J, Smith M.E, Kaufman P.L. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res. 1999;69:385-395.
72. Challa P, Luna C, Liton P.B, et al. Lentiviral mediated gene delivery to the anterior chamber of rodent eyes. Mol Vis. 2005;11:425-430.
73. Balaggan K.S, Binley K, Esapa M, et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J Gene Med. 2006;8:275-285.